ArteraAI

Dr. Daniel Spratt on Artera’s Post‑RP test: “[It] uses clinical and pathologic features + digital pathology, running AI to help ID patients at low vs high risk of recurrence and metastasis.” Thanks @UroTimes + Hannah Clarke for the feature. heyor.ca/mI71pa #ArteraAI

Clarity matters in clinical decision-making. Grateful to hear how the #ArteraAI Prostate Test is supporting real-world practice. #ProstateCancer #AIinHealthcare

We’re heading to the APG Spring Conference in San Diego this month. Looking forward to connecting with healthcare leaders on value-based care, population health, and the role of AI in oncology. #APG2026 #ValueBasedCare #ArteraOnTheGo

If you treat localized #prostatecancer, consider incorporating the #ArteraAI Prostate Test into multidisciplinary decisions, especially around treatment intensification. It augments, not replaces, clinical judgment. Read more in this @Medscape article: buff.ly/hiTrpuh

Next stop: #ASCO26 We’re excited to join leaders across #oncology to discuss the latest research, innovation, and the evolving role of AI in clinical care. See you there. #PrecisionOncology #DigitalHealth #ArteraOnTheGo

Genomic classifiers and AI for personalizing #ProstateCancer radiation therapy. @drjefstathiou @MassGenBrigham joins @neerajaiims @huntsmancancer to discuss the use of genomic classifiers and AI-based tools in personalizing radiation therapy for prostate cancer. #WatchNow on UroToday > bit.ly/422l2Ue #APCCC26 @Decipher_VCYT @APCCC_Lugano @arteraAI

Pathology AI-based prognostic tests continue to roll out. @arteraAI has one of the best known FDA-cleared/CE marked prostate cancer prognostic tests and CPT III coding for it. They have just received FDA clearance for their new breast product that predicts distant metastasis in early-stage, hormone-positive, HER2- breast cancer based on pathology slide analysis. 1) This makes FDA clearance easier for similar products in the breast space -- there are other good companies working in this space. 2) If they manage a CPTIII code for this one too, there is a valid reimbursement pathway for breast path AI predictive tests. businesswire.com/news/home/2026…

Cancer care isn’t just about survival, it’s about quality of life. In this piece, Artera’s VP of Medical Science, Calvin Chao, explores how AI-enabled pathology is helping personalize treatment decisions. Read more: buff.ly/TGeQlMw #ProstateCancer #ArteraAI

We have received FDA clearance for #ArteraAI Breast, expanding our AI platform into #breastcancer. A key step in bringing personalized, data-driven insights to more patients. Learn more: buff.ly/KdzRwUC #AIinHealthcare #PrecisionMedicine

We’re heading to #AUA2026 in Washington, DC this month. Looking forward to connecting with the urology community and continuing the conversation around precision #prostatecancer care. #ArteraOnTheGo

Miss our latest product webinar? Watch Drs. Ken Nepple, Murilo de Almeida Luz, and Ben Fischer-Valuck discuss how they’re using the #ArteraAI Prostate Test and its impact on salvage radiation decisions. Watch now: buff.ly/Vco5Hp3

As AI enters clinical care, regulation is evolving with it. New from Katie Palmer @ STAT: how the FDA’s approach to breakthrough AI medical devices is shifting — and what that means for the future of adoption. Read more: buff.ly/fEZfxh7 #AIinHealthcare #ArteraAI

Multimodal AI is gaining momentum in oncology. New CAP TODAY coverage highlights ASCO research exploring how AI models can support cancer diagnostics and treatment decisions. Read more: buff.ly/Aqc4s5w #AIinHealthcare #DigitalPathology #ArteraAI #PrecisionMedicine

We’re looking forward to connecting with clinicians and partners across several upcoming meetings this May and continuing conversations around AI-powered precision care in #prostatecancer. Visit buff.ly/bRYpS3K to see more of our upcoming events. #ArteraOnTheGo

We’re heading to Docs That Rock in NY! We're proud to support this great initiative bringing the urology community together through connection, collaboration, and a shared commitment to patient care. #Urology #ProstateCancer #ArteraOnTheGo

New JNCI study: using the #ArteraAI Prostate Test to guide ADT use may reduce costs by >$12K vs. other treatment approaches. Read more: buff.ly/6ZrxN9w #ProstateCancer #PrecisionMedicine

Celebrating #LabWeek and the incredible Artera lab team. Your expertise, precision, and dedication help power better decisions for patients every day. Thank you for all you do.

We’re heading to the American Radium Society Annual Meeting. Looking forward to connecting with the radiation oncology community and continuing the conversation on AI-powered cancer care. #RadiationOncology #AIinHealthcare #ArteraOnTheGo

A major milestone for Artera! We’ve achieved CE marking for ArteraAI Breast Cancer Assay and ArteraAI Prostate Biopsy Assay, the first and only AI-enabled prognostic and predictive #prostatecancer SaMD available in the EU. Read the full announcement: buff.ly/nWYbkve

We’ve updated our homepage, including a new page on our work in #breastcancer. As we expand beyond prostate cancer, we’re bringing AI-driven insights to more areas of oncology. See it live: artera.ai/breast-cancer-… #ArteraAI #PrecisionMedicine

New Active Surveillance (AS) Insights on the #ArteraAI Prostate Test Report, validated in a modern, real-world AS-managed cohort published in Reviews in Urology. Read the updated report: buff.ly/q8CjOTS #PrecisionOncology #ProstateCancer